Cargando…

Effects of Levocarnitine on Brachial-Ankle Pulse Wave Velocity in Hemodialysis Patients: A Randomized Controlled Trial

Background and Aims: Atherosclerotic cardiovascular disease is the most common cause of mortality in patients with end-stage kidney disease. Chronic kidney disease patients often exhibit a deficiency in l-carnitine due to loss during hemodialysis (HD). We studied the effects of l-carnitine supplemen...

Descripción completa

Detalles Bibliográficos
Autores principales: Higuchi, Terumi, Abe, Masanori, Yamazaki, Toshio, Mizuno, Mari, Okawa, Erina, Ando, Hideyuki, Oikawa, Osamu, Okada, Kazuyoshi, Kikuchi, Fumito, Soma, Masayoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277011/
https://www.ncbi.nlm.nih.gov/pubmed/25533009
http://dx.doi.org/10.3390/nu6125992
_version_ 1782350337884028928
author Higuchi, Terumi
Abe, Masanori
Yamazaki, Toshio
Mizuno, Mari
Okawa, Erina
Ando, Hideyuki
Oikawa, Osamu
Okada, Kazuyoshi
Kikuchi, Fumito
Soma, Masayoshi
author_facet Higuchi, Terumi
Abe, Masanori
Yamazaki, Toshio
Mizuno, Mari
Okawa, Erina
Ando, Hideyuki
Oikawa, Osamu
Okada, Kazuyoshi
Kikuchi, Fumito
Soma, Masayoshi
author_sort Higuchi, Terumi
collection PubMed
description Background and Aims: Atherosclerotic cardiovascular disease is the most common cause of mortality in patients with end-stage kidney disease. Chronic kidney disease patients often exhibit a deficiency in l-carnitine due to loss during hemodialysis (HD). We studied the effects of l-carnitine supplementation on brachial-ankle pulse wave velocity (baPWV), a marker of atherosclerosis, in HD patients. Methods: This was a prospective, open-label, randomized, parallel controlled, multi-center trial testing the anti-atherosclerotic efficacy of oral l-carnitine administration (20 mg/kg/day). HD patients (n = 176, mean age, 67.2 ± 10.3 years old; mean duration of HD, 54 ± 51 months) with plasma free l-carnitine deficiency (<40 μmol/L) were randomly assigned to the oral l-carnitine group (n = 88) or control group (n = 88) and monitored during 12 months of treatment. Results: There were no significant differences in baseline clinical variables between the l-carnitine and control groups. l-carnitine supplementation for 12 months significantly increased total, free, and acyl carnitine levels, and reduced the acyl/free carnitine ratio. The baPWV value decreased from 2085 ± 478 cm/s at baseline to 1972 ± 440 cm/s after six months (p < 0.05) to 1933 ± 363 cm/s after 12 months (p < 0.001) of l-carnitine administration, while no significant changes in baPWV were observed in the control group. Baseline baPWV was the only factor significantly correlated with the decrease in baPWV. Conclusions: l-carnitine supplementation significantly reduced baPWV in HD patients. l-carnitine may be a novel therapeutic strategy for preventing the progression of atherosclerotic cardiovascular disease.
format Online
Article
Text
id pubmed-4277011
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-42770112015-01-15 Effects of Levocarnitine on Brachial-Ankle Pulse Wave Velocity in Hemodialysis Patients: A Randomized Controlled Trial Higuchi, Terumi Abe, Masanori Yamazaki, Toshio Mizuno, Mari Okawa, Erina Ando, Hideyuki Oikawa, Osamu Okada, Kazuyoshi Kikuchi, Fumito Soma, Masayoshi Nutrients Article Background and Aims: Atherosclerotic cardiovascular disease is the most common cause of mortality in patients with end-stage kidney disease. Chronic kidney disease patients often exhibit a deficiency in l-carnitine due to loss during hemodialysis (HD). We studied the effects of l-carnitine supplementation on brachial-ankle pulse wave velocity (baPWV), a marker of atherosclerosis, in HD patients. Methods: This was a prospective, open-label, randomized, parallel controlled, multi-center trial testing the anti-atherosclerotic efficacy of oral l-carnitine administration (20 mg/kg/day). HD patients (n = 176, mean age, 67.2 ± 10.3 years old; mean duration of HD, 54 ± 51 months) with plasma free l-carnitine deficiency (<40 μmol/L) were randomly assigned to the oral l-carnitine group (n = 88) or control group (n = 88) and monitored during 12 months of treatment. Results: There were no significant differences in baseline clinical variables between the l-carnitine and control groups. l-carnitine supplementation for 12 months significantly increased total, free, and acyl carnitine levels, and reduced the acyl/free carnitine ratio. The baPWV value decreased from 2085 ± 478 cm/s at baseline to 1972 ± 440 cm/s after six months (p < 0.05) to 1933 ± 363 cm/s after 12 months (p < 0.001) of l-carnitine administration, while no significant changes in baPWV were observed in the control group. Baseline baPWV was the only factor significantly correlated with the decrease in baPWV. Conclusions: l-carnitine supplementation significantly reduced baPWV in HD patients. l-carnitine may be a novel therapeutic strategy for preventing the progression of atherosclerotic cardiovascular disease. MDPI 2014-12-22 /pmc/articles/PMC4277011/ /pubmed/25533009 http://dx.doi.org/10.3390/nu6125992 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Higuchi, Terumi
Abe, Masanori
Yamazaki, Toshio
Mizuno, Mari
Okawa, Erina
Ando, Hideyuki
Oikawa, Osamu
Okada, Kazuyoshi
Kikuchi, Fumito
Soma, Masayoshi
Effects of Levocarnitine on Brachial-Ankle Pulse Wave Velocity in Hemodialysis Patients: A Randomized Controlled Trial
title Effects of Levocarnitine on Brachial-Ankle Pulse Wave Velocity in Hemodialysis Patients: A Randomized Controlled Trial
title_full Effects of Levocarnitine on Brachial-Ankle Pulse Wave Velocity in Hemodialysis Patients: A Randomized Controlled Trial
title_fullStr Effects of Levocarnitine on Brachial-Ankle Pulse Wave Velocity in Hemodialysis Patients: A Randomized Controlled Trial
title_full_unstemmed Effects of Levocarnitine on Brachial-Ankle Pulse Wave Velocity in Hemodialysis Patients: A Randomized Controlled Trial
title_short Effects of Levocarnitine on Brachial-Ankle Pulse Wave Velocity in Hemodialysis Patients: A Randomized Controlled Trial
title_sort effects of levocarnitine on brachial-ankle pulse wave velocity in hemodialysis patients: a randomized controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277011/
https://www.ncbi.nlm.nih.gov/pubmed/25533009
http://dx.doi.org/10.3390/nu6125992
work_keys_str_mv AT higuchiterumi effectsoflevocarnitineonbrachialanklepulsewavevelocityinhemodialysispatientsarandomizedcontrolledtrial
AT abemasanori effectsoflevocarnitineonbrachialanklepulsewavevelocityinhemodialysispatientsarandomizedcontrolledtrial
AT yamazakitoshio effectsoflevocarnitineonbrachialanklepulsewavevelocityinhemodialysispatientsarandomizedcontrolledtrial
AT mizunomari effectsoflevocarnitineonbrachialanklepulsewavevelocityinhemodialysispatientsarandomizedcontrolledtrial
AT okawaerina effectsoflevocarnitineonbrachialanklepulsewavevelocityinhemodialysispatientsarandomizedcontrolledtrial
AT andohideyuki effectsoflevocarnitineonbrachialanklepulsewavevelocityinhemodialysispatientsarandomizedcontrolledtrial
AT oikawaosamu effectsoflevocarnitineonbrachialanklepulsewavevelocityinhemodialysispatientsarandomizedcontrolledtrial
AT okadakazuyoshi effectsoflevocarnitineonbrachialanklepulsewavevelocityinhemodialysispatientsarandomizedcontrolledtrial
AT kikuchifumito effectsoflevocarnitineonbrachialanklepulsewavevelocityinhemodialysispatientsarandomizedcontrolledtrial
AT somamasayoshi effectsoflevocarnitineonbrachialanklepulsewavevelocityinhemodialysispatientsarandomizedcontrolledtrial